Sending the same vial twice, under two names
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 25 of 25 of this archive, newest first.
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Efficacy was never the question in this appraisal. Duration of treatment was.
Efficacy was never the question in this appraisal. Duration of treatment was.
The commonest real-world strategy in this drug class is the least studied one.
Efficacy was never the question in this appraisal. Duration of treatment was.
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Efficacy was never the question in this appraisal. Duration of treatment was.